ORIC Pharmaceuticals (NASDAQ:ORIC) Stock Rating Reaffirmed by Wedbush

ORIC Pharmaceuticals (NASDAQ:ORIC)‘s stock had its “outperform” rating reaffirmed by investment analysts at Wedbush in a research report issued to clients and investors on Monday, RTT News reports. They presently have a $20.00 target price on the stock. Wedbush’s price objective would suggest a potential upside of 141.55% from the company’s previous close.

A number of other research analysts also recently commented on ORIC. Cantor Fitzgerald restated an “overweight” rating on shares of ORIC Pharmaceuticals in a research note on Thursday, June 20th. Oppenheimer restated an “outperform” rating and set a $17.00 price objective on shares of ORIC Pharmaceuticals in a research note on Wednesday, July 10th. Citigroup lowered their price objective on ORIC Pharmaceuticals from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday, May 7th. Finally, HC Wainwright restated a “buy” rating and set a $21.00 price objective on shares of ORIC Pharmaceuticals in a research note on Wednesday, July 17th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $19.50.

ORIC Pharmaceuticals Trading Down 1.3 %

ORIC traded down $0.11 during trading on Monday, reaching $8.28. 247,433 shares of the company were exchanged, compared to its average volume of 542,159. The stock has a market cap of $558.25 million, a P/E ratio of -4.60 and a beta of 1.13. The firm has a 50 day moving average of $8.89 and a 200 day moving average of $10.36. ORIC Pharmaceuticals has a 52 week low of $5.27 and a 52 week high of $16.65.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ORIC. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in ORIC Pharmaceuticals by 162.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock valued at $36,000 after buying an additional 3,188 shares in the last quarter. AJOVista LLC bought a new position in ORIC Pharmaceuticals during the fourth quarter valued at about $40,000. Strs Ohio bought a new position in ORIC Pharmaceuticals during the fourth quarter valued at about $72,000. Quest Partners LLC boosted its stake in ORIC Pharmaceuticals by 253.2% during the second quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock valued at $73,000 after buying an additional 7,440 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in ORIC Pharmaceuticals during the second quarter valued at about $153,000. Institutional investors and hedge funds own 95.05% of the company’s stock.

ORIC Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.